Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2011; 3(02): 075-079
DOI: 10.4103/0974-2727.86837
Review Article

Models of Latent Tuberculosis: Their Salient Features, Limitations, and Development

Kamlesh Patel
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Punjab, India
,
Sarbjit Singh Jhamb
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Punjab, India
,
Prati Pal Singh
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Punjab, India
› Author Affiliations Source of Support: Nil
› Further Information
  PDF Download Permissions and Reprints

ABSTRACT

Latent tuberculosis is a subclinical condition caused by Mycobacterium tuberculosis, which affects about one-third of the population across the world. To abridge the chemotherapy of tuberculosis, it is necessary to have active drugs against latent form of M. tuberculosis. Therefore, it is imperative to devise in vitro and models of latent tuberculosis to explore potential drugs. In vitro models such as hypoxia, nutrient starvation, and multiple stresses are based on adverse conditions encountered by bacilli in granuloma. Bacilli experience oxygen depletion condition in hypoxia model, whereas the nutrient starvation model is based on deprivation of total nutrients from a culture medium. In the multiple stress model dormancy is induced by more than one type of stress. In silico mathematical models have also been developed to predict the interactions of bacilli with the host immune system and to propose structures for potential anti tuberculosis compounds. Besides these in vitro and in silico models, there are a number of in vivo animal models like mouse, guinea pig, rabbit, etc. Although they simulate human latent tuberculosis up to a certain extent but do not truly replicate human infection. All these models have their inherent merits and demerits. However, there is no perfect model for latent tuberculosis. Therefore, it is imperative to upgrade and refine existing models or develop a new model. However, battery of models will always be a better alternative to any single model as they will complement each other by overcoming their limitations.

Keywords

In vitro - In vivo - latent tuberculosis - M. tuberculosis - model


Publication History

Article published online:
09 May 2020

© 2011.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • REFERENCES

  • 1 Miyazaki E, Chaisson RE, Bishai WR. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. Antimicrob Agents Chemother 1999;43:2126-30.
  • 2 Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuermberger EL, Grosset J, et al. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med 2004;200:647-57.
  • 3 Currie CS, Floyd K, Williams BG, Dye C. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health 2005;5:130-46.
  • 4 Parrish NM, Dick JD, Bishai WR. Mechanisms of latency in Mycobacterium tuberculosis. Trends in Microbiology 1998;6:107-12.
  • 5 Flynn JL, Chan J. Tuberculosis: Latency and Reactivation. Infect Immun 2001;69:4195-201.
  • 6 Karakousis PC, Williams EP, Bishai WR. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Chemo 2008;61:323-31.
  • 7 Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996;64:2062-9.
  • 8 Hu YM, Butcher PD, Sole K, Mitchison DA, Coates AR. Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Lett 1998;158:139-45.
  • 9 Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994;38:2054-8.
  • 10 Wayne LG. Synchronized replication of Mycobacterium tuberculosis. Infect Immun 1977;17:528-30.
  • 11 Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005;49:2294-301.
  • 12 Jhamb SS, Singh RP, Singh PP. A comparison of conventional and radiometric methods for the assessment of anti-tubercular activity of drugs against Mycobacterium tuberculosis in mice and macrophage models. Indian J Tuberc 2008;55:70-6.
  • 13 Wayne LG, Hayes LG. Nitrate reduction as a marker for hypoxic shiftdown of Mycobacterium tuberculosis. Tuberc Lung Dis 1998;79:127-32.
  • 14 Archuleta RJ, Yvonne Hoppes P, Primm TP. Mycobacterium avium enters a state of metabolic dormancy in response to starvation. Tuberculosis 2005;85:147-58.
  • 15 Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002;43:717-31.
  • 16 Murphy DJ, Brown JR. Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. BMC Infect Dis 2007;7:84-100.
  • 17 Ahmad Z, Sharma S, Khuller GK. The potential of azole antifungals against latent/persistent tuberculosis. FEMS microbiology letters 2006;258:200-3.
  • 18 Huang Q, Chen ZF, Li YY, Zhang Y, Ren Y, Fu Z, et al. Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. Chemotherapy 2007;53:338-43.
  • 19 Deb C, Lee CM, Dubey V, Daniel J, Abomoelak B, Sirakova T, et al. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. pLoS ONE 2009;4:e6077.
  • 20 Reddy M, Srinivasan S, Andersen B, PR G. Rapid assessment of mycobacterial growth inside macrophages and mice, using the radiometric (BACTEC) method. Tuber Lung Dis 1994;75:127-31.
  • 21 Alcaide F, Benýtez MA, Escriba JM , Martýn R. Evaluation of the BACTEC MGIT 960 and the MB/BacT systems for recovery of mycobacteria from clinical specimens and for species identification by DNA Accu-Probe. J Clin Microbiol 2000;38:398-401.
  • 22 Lin Ling P, Kirschner D, Flynn JL. Modeling pathogen and host: in vitro, in vivo and in silico models of latent Mycobacterium tuberculosis infection. Inflamm Infect Dis 2005;2:149-54.
  • 23 Kirschner D, Marino S. Mycobacterium tuberculosis as viewed through a computer. Trends Microbiol 2005;13:206-11.
  • 24 Gupta UD, Katoch VM. Animal models of tuberculosis. Tuberculosis (Edinb) 2005;85:277-93.
  • 25 Miyazaki E, Chaisson R, Bishai W. Analysis of Rifapentine for preventive therapy in the cornell mouse model of latent tuberculosis. Antimicrob Agents Chemother 1999;43:2126-30.
  • 26 Dhillon J, Allen BW, Hu YM, Coates AR, Mitchison DA. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis 1998;2:736-42.
  • 27 Flynn JL, Scanga CA, Tanaka KE, Chan J. Effects of aminoguanidine on latent murine tuberculosis. J Immunol 1998;160:1796-803.
  • 28 Phyu S, Mustafa T, Hofstad T, Nilsen R, Fosse R , Bjune G. A mouse model for latent tuberculosis. Scand J Infect Dis 1998;30:59-68.
  • 29 Ordway D, Henao-Tamayo M, Shanley C, Smith EE, Palanisamy G, Wang B, et al. Influence of Mycobacterium bovis BCG vaccination on cellular immune response of guinea pigs challenged with Mycobacterium tuberculosis. Clin Vaccine Immunol 2008;15:1248-58.
  • 30 Lenaerts AJ, Hoff D, Aly S, Ehlers S, Andries K, Cantarero L, et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 2007;51:3338-45.
  • 31 Sugawara I, Udagawa T, Aoki T, Mizuno S. Establishment of a guinea pig model of latent tuberculosis with GFP-introduced Mycobacterium tuberculosis. Tohoku J Exp Med 2009;219:257-62.
  • 32 Kashino SS, Napolitano DR, Skobe Z, Campos-Neto A. Guinea pig model of Mycobacterium tuberculosis latent/dormant infection. Microbes Infect 2008;10:1469-76.
  • 33 Manabe YC, Kesavan AK, Lopez-Molina J, Hatem CL, Brooks M, Fujiwara R, et al. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis 2008;88:187-96.
  • 34 Lin PL, Kirschner D, Flynn JL. Modeling pathogen and host: in vitro, in vivo and in silico models of latent Mycobacterium tuberculosis infection. Drug Discov Today: Dis Models 2005;2:149-54.
  • 35 Capuano SV 3rd, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 2003;71:5831-44.
  • 36 Flynn JL, Capuano SV, Croix D, Pawar S, Myers A, Zinovik A, et al. Non-human primates: A model for tuberculosis research. Tuberculosis (Edinb) 2003;83:116-8.